Literature DB >> 15764169

In vitro inhibition of SARS virus replication by human interferons.

Helena Dahl1, Annika Linde, Orjan Strannegård.   

Abstract

Four different types of human interferon, interferon-beta (IFN-beta), recombinant IFN-alpha2a and IFN-alpha2b and natural IFN-alpha were tested for antiviral activity against SARS-coronavirus. The experiments were performed using in vitro cultivated monkey Vero E6 cells. IFN-beta was found to be the most highly active antiviral agent, followed by natural IFN-alpha, whereas the 2 recombinant IFN-alpha2 species were poorly active in the system used. These results suggest that IFN-beta as well as natural IFN-alpha may be used for the treatment of SARS.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15764169     DOI： 10.1080/00365540410021144

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN： 0036-5548


  20 in total

1.  Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures.

Authors:  Renee W Y Chan; Michael C W Chan; Sudhakar Agnihothram; Louisa L Y Chan; Denise I T Kuok; Joanne H M Fong; Y Guan; Leo L M Poon; Ralph S Baric; John M Nicholls; J S Malik Peiris
Journal:  J Virol       Date:  2013-04-03       Impact factor: 5.103

Review 2.  Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection.

Authors:  Vincent C C Cheng; Susanna K P Lau; Patrick C Y Woo; Kwok Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

Review 3.  The Immune Responses against Coronavirus Infections: Friend or Foe?

Authors:  Arefe Vafaeinezhad; Mohammad Reza Atashzar; Rasoul Baharlou
Journal:  Int Arch Allergy Immunol       Date:  2021-05-05       Impact factor: 2.749

4.  Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model.

Authors:  Yohichi Kumaki; Jane Ennis; Ramtin Rahbar; Jeffrey D Turner; Miles K Wandersee; Aaron J Smith; Kevin W Bailey; Zachary G Vest; Jason R Madsen; Joseph K-K Li; Dale L Barnard
Journal:  Antiviral Res       Date:  2010-11-18       Impact factor: 5.970

Review 5.  Interim Guidelines on Antiviral Therapy for COVID-19.

Authors:  Sun Bean Kim; Kyungmin Huh; Jung Yeon Heo; Eun Jeong Joo; Youn Jeong Kim; Won Suk Choi; Yae Jean Kim; Yu Bin Seo; Young Kyung Yoon; Nam Su Ku; Su Jin Jeong; Sung Han Kim; Kyong Ran Peck; Joon Sup Yeom
Journal:  Infect Chemother       Date:  2020-04-23

Review 6.  Development of antiviral therapy for severe acute respiratory syndrome.

Authors:  Jindrich Cinatl; Martin Michaelis; Gerold Hoever; Wolfgang Preiser; Hans Wilhelm Doerr
Journal:  Antiviral Res       Date:  2005-04-26       Impact factor: 5.970

7.  Antiviral activities of type I interferons to SARS-CoV-2 infection.

Authors:  Emily Mantlo; Natalya Bukreyeva; Junki Maruyama; Slobodan Paessler; Cheng Huang
Journal:  Antiviral Res       Date:  2020-04-29       Impact factor: 5.970

Review 8.  Coronavirus virulence genes with main focus on SARS-CoV envelope gene.

Authors:  Marta L DeDiego; Jose L Nieto-Torres; Jose M Jimenez-Guardeño; Jose A Regla-Nava; Carlos Castaño-Rodriguez; Raul Fernandez-Delgado; Fernando Usera; Luis Enjuanes
Journal:  Virus Res       Date:  2014-08-02       Impact factor: 3.303

Review 9.  Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19.

Authors:  Madalina Elena Carter-Timofte; Sofie Eg Jørgensen; Mette Ratzer Freytag; Michelle Mølgaard Thomsen; Nanna-Sophie Brinck Andersen; Ali Al-Mousawi; Alon Schneider Hait; Trine H Mogensen
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

Review 10.  The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.

Authors:  David Baker; Sandra Amor; Angray S Kang; Klaus Schmierer; Gavin Giovannoni
Journal:  Mult Scler Relat Disord       Date:  2020-05-12       Impact factor: 4.339
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.